One Nucleus Autumn ON Highlights 2015

Autumn 2015

When Richard Burton was first introduced to Elizabeth Taylor, the story goes that he laughed out loud – later explaining that it was his natural reaction to her ridiculous beauty. Driving into work at Granta Park early this morning for a breakfast meeting, I kind of get what he meant – the view from the front gate was absolutely spectacular, with the trees all in full Autumn glow and I did the same.

It is a visual pleasure to work here and also hugely exciting right now given the news of major expansion – not least Illumina’s fantastic new Europe, Middle East and Africa HQ build – the ground of which was broken today (21 October) in the company of the world’s only

Cambridge UK

Welcome

with Babraham BioScience Technologies, Chesterford Research Park, London BioScience Innovation Centre, Queen Mary BioEnterprises and Stevenage BioScience Catalyst as well as informal relations with a wide

plans and strategy for the park and all its parts.

I hope you all continue to enjoy our twice yearly ON Highlights.

The team and I so enjoy reflecting on our members’ success in the six months since the last newsletter was created. The pace of growth, innovation and ‘We continue to broaden and deepen our change is staggering and many international connections for tangible member of our members are telling us benefit.’ that they have radically amended their expansion plans in the last year or so, to take account of Minister for Life Sciences, good range of others around the UK. friend of One Nucleus, George Our most recent partner is Norwich the burgeoning sector and the Freeman MP. Research Park – I witnessed some strong mood-music that this is no bubble, given that many both stunning technology taking place Other science parks and US-side and around the world are there during my recent visit and incubators are of course available our lead interview is with Sally-Ann predicting sustainable growth over (!) and One Nucleus delights the coming years. Hurrah to that – Forsyth, the relatively new Chief in having partnerships in place after such trying recent years for Executive who expands on her

IN THIS ISSUE

1

Norwich Research Park

Sally Ann Forsyth, CEO: Passionate about leading edge technology

4

The Francis Crick Institute

The view from St Pancras: We hear from David Roblin, COO and Director of Translation

22

Zyme Communications

Celebrating the company’s first 5 years

2

Member News

Autumn 2015

Cambridge, Massachusetts, USA

on 10 December and our annual Genesis Conference. Masterminded as ever by Tony Jones, our indefatigable Director of Business Development, the programme is set, the speakers all confirmed, the exhibition space nearly full and the green ‘go’ button ready to be pressed. For a review of Genesis 2014 and to find out more about Genesis 2015, do check out page 23.

many of you - not that it is easy for anyone of course.

At One Nucleus we recognise that now is no time for anyone to sit back and we continue to broaden and deepen our international connections for tangible member benefit. Looking to the US in particular, and building on our relations with MassBIO, MassMedic, CLSA (the new name for BayBIO) and BIOCOM, in recent months we have forged new partnerships with Bio New Jersey (after we were honoured to host a visit of their Governor, Chris Christie here at One Nucleus back in February), Life Sciences British Columbia and Pennsylvania Bio – all of which mean our members have ‘critical friends’ in those markets if they are looking to do business there, and vice versa.

As I pen this introduction, the One Nucleus team is busy looking at our two major events of the year.

Firstly - ON Helix (our Cambridge based annual translational research conference) which took place in July. Do read all about it on page 24. We were the very first event to be held at the Wellcome Genome Campus Conference Centre after their two year refurbishment. I have to admit to minor nerves that the sprinklers might go off at any moment, or the audio not work, but I shouldn’t have worried – Linda, Kelly and the conference team couldn’t have been more prepared and the event, with a capacity guest list, ran completely smoothly.

We are now working on 2016 and are delighted that we already have our keynote speakers confirmed – Sir John Savill, CEO of the MRC, Dr Susan Windham-Bannister, exPresident of the Massachusetts Life Sciences Center (and responsible for delivering the $1 billion programme for life sciences in the Mass area) and David Roblin, COO of the Crick Institute. Do check out what occupies his thoughts on a daily basis in our second lead interview on page 5. I was fortunate to be invited for a guided tour of the Crick last month and whilst it is still in the ‘build’ stage, what was most impressive was the fact that all the labs are already ‘good to go’. I guess that is what happens when world leading science is at the forefront of a strategy! Each scientist who will

At One Nucleus we are always interested in working in collaboration with those who have a similar mind set where there is a clear benefit for our members.

Two great examples of this in recent months were our Amgen Day (where we brought Amgen leadership together with over 230 from the sector) and our collaboration with John Carroll, Editor in Chief of FierceBiotech just a week ago – where we supported him in bringing over 300 executives together to analyse the UK market with a particular emphasis on finance. We have lots of similar collaborations planned for the rest of the year, not least with the Genesis Fringe (page 23) and can’t wait for 2016. Do watch out for details of similar opportunities in our weekly eNews.

Finally, I know many of you will be busy planning for JP Morgan in January. Do remember our

‘We all have our eyes firmly fixed on 10 December and our annual Genesis Conference.’

occupy the building has already been identified. Each will have their own bench space, each with their own individual and bespoke technical requirements fitted into their dashboard – easily removable so they can move around the building and collaborate and mix – this rubbing of shoulders goes to the heart of what the Crick will be all about.

Secondly for the One Nucleus team, we all have our eyes firmly fixed

fantastic arrangement with the Flight Centre Business Travel which sees our members receiving significant discounts off flights and accommodation. I have booked already and saved literally hundreds of pounds with them. The link to the great FCBT team is here http:// www.onenucleus.com/download. aspx?id=1597

Member News

Autumn 2015

3

A Foundation for Success Dr Sally Ann Forsyth, Chief Executive of Norwich Research Park

My role as CEO is to build upon this fantastic foundation and create a networked supportive environment that adds value to business and attracts even more innovative companies in the future.

Prior to joining NRP, I was Director of Science Parks for International Property Group Goodman. I was responsible for the strategic direction, management and performance of Goodman’s Science Park portfolio with an active role as Director for Colworth Park, Bedfordshire and Harwell Oxford, Oxfordshire.

One Nucleus talks to Dr Sally Ann Forsyth, Chief Executive of Norwich Research Park, about life on the Park and ambitious plans for the future.

Tell us a little about your background and your role at Norwich Research Park It may sound a little clichéd but Norwich Research Park (NRP) truly is a unique location; currently home to 3,000 scientists and clinicians integrated alongside over 40 growing businesses. This networked cluster is made up of some of the finest scientific and innovative people in the world; all located within a 1 km radius of each other.

My career started with Unilever as a management trainee and covered a range of roles including internal consultant with postings in Africa and Asia, Head of Technology Licensing and finally Principle with Unilever Ventures working on technology spin-outs and investments.

What prompted your move to NRP and what particularly excites you about the research park?

NRP is an area of 230 hectares which is home to the six partner organisations comprising four world leading research institutes; John Innes Centre (JIC), Institute of Food Research (IFR), The Genome Analysis Centre (TGAC) and The Sainsbury Laboratory (TSL),

together with the University of East Anglia (UEA) and the Norfolk and Norwich University Hospital (NNUH).

Norwich Research Partners LLP was formed in 2012, with the support of these partner organisations plus the John Innes Foundation (JIF) and the Biotechnology and Biological Science Research Council (BBSRC) to develop a supportive innovation environment innovation and deliver a world class location for research, science and business. With this strong partnership in place the time was right to take up this unique and exciting opportunity.

The vision to deliver solutions to global challenges such as healthy ageing, diet related diseases and food security really appeals to me. By working together the partner organisations are able to bring together a range of skills and leading edge technologies to address these issues using for example advanced genomics, systems biology and manipulation of the gut microbiome.

I am also passionate about getting leading edge technology out to the end user, so being part of an organisation which supports that innovation supply chain is very exciting. With new technology, if you read about it in a patent or see it in a paper you are too late – you have to be where the breaking wave of technology is and that is really

(Continued on page 4)

4

Member News

exciting.

It is much more than a property play; it is the people and their interaction that add real value to businesses.

Autumn 2015 development from initial start-up in a shared building to an independent company in standalone premises right here on the Park.

Investment has also been made in developing the Enterprise Centre With your significant experience, at UEA, which has been set up what are the challenges that specifically to help incubate start-up face science parks in general? businesses and in the construction of the Bob Champion Research and Science and research parks play Education Building which houses an important role in regional researchers focused on finding new development, helping bring treatments for diseases affecting research to life by supporting ageing populations as well as a the development of spin out and unique bio-repository facility which existing businesses. However like all businesses, economic downturns provides sample access by our occupiers. can have an impact on growth.

Science parks tend to be more Planning consent was recently attractive than business parks at granted for a new Centre for these times due to the added value Food and Health, which will bring support that they can offer. together the Institute of Food

The Clinical Trials Unit is also undergoing an expansion to take advantage of a growing pipeline of investigative compounds that can be taken from early to late stage using technology, development and trials expertise across the Park. Established by UEA and NNUH, it is a key asset. An effective platform for the conduct of high quality clinical trials, it also provides a forum for training and methodological advancement in trial design, conduct and analysis.

Research with aspects of the University’s Medical School and Another development is Leaf Faculty of Science with the hospitals Systems, a translational facility gastrointestinal endoscopy facility. for research, development

Here at NRP all of our plans are linked to long term growth of our occupiers and job creation which will pay dividends in the years to come.

What plans do you have for NRP? I joined the Park in September 2013 and it has been a really exhilarating journey.

It began with the opening of Centrum in July 2014. An innovation and enterprise hub, Centrum has a natural buzz and is a real place for knowledge exchange; this can be on an informal level over a coffee in the cafĂŠ or from attending a seminar in one of the meeting rooms.

The aim has been to create a comprehensive portfolio of accommodation that will provide opportunities for companies to locate here at any stage in their

The output of the new centre will lead to improved human health, the production of nutritionally enhanced crop-based food and accelerate commercial development by UK industry. It will also enable us to work with more volunteers for food and clinical trials, and will attract food, pharma and fast-moving consumer goods companies that need to acquire understanding and evidence of the effects of products on gastrointestinal process.

and manufacture of high value products in plants. This ÂŁ7 million development is supported by the BBSRC, John Innes Centre, Plant Bioscience Ltd (PBL) and NRP.

Dr Sally Ann Forsyth and Jonathan Barnard of NRP with Steve Moon

(seated) and Gerard Mulqueen of Germains Seed Technology

Small companies in particular have very little time and no money.

We therefore provide business support and access to equipment through shared laboratories and our equipment portal which companies use to access more specialist equipment and expertise across the Park. It is a question of providing the right support, at the right time, at the right price, or preferably free.

Work on the new building is due to start in the autumn ahead of the planned opening in late 2017. It will accommodate approximately 300 science-related posts as well as providing a regional gastrointestinal endoscopy facility for 40,000 patients each year.

Member News

Autumn 2015

5

Accelerating Translation for Health and Wealth Francis Crick Institute (the Crick)

Firstly, in the UK not enough of our basic researchers have experience of translation. This compares with the US where around a third of researchers have had experiences such as creating a spin-out company, which equips them with a broader range of skills. The Crick has developed a concept of ‘close distance translation’, which will bring applied researchers with industrial experience into the labs of our basic researchers to help identify and move forward potentially translatable science.

Located in central London, the new Francis Crick Institute (the Crick) will provide state-of-the-art facilities for over 1,800 scientists.

The building has been designed to promote connections and interactions between researchers from different disciplines and between academic institutions, healthcare organisations and businesses in order to aid the translation of basic research into the creation of healthcare products. One Nucleus interviewed David Roblin, Chief Operating Officer and Director of Scientific Translation at the Crick about his role and the work of the Institute.

Tell us a little about your background and your role as COO and Director of Scientific Translation At the start of my career, I spent five years practising medicine before entering the pharmaceutical industry where I held roles in research, development and on the commercial side. I was lucky to be a part of R&D teams that brought several new medicines to patients world-wide, which I found very rewarding. My final two years at Pfizer were as senior Vice-President,

Secondly, technology transfer takes too long in the UK, particularly in the earliest stages of science when failure is more likely. We will develop a technology transfer group Head of Research for Pfizer’s European R&D. I left in early 2011, that focuses on putting discoveries and was subsequently Chief Medical into capable hands more quickly, rather than on early financial Officer and Non-Executive Director returns. to a number of biotechs before joining the Crick in February 2014.

What is the mission and purpose As Chief Operating Officer, I ensure that the Crick runs efficiently, that our science platforms work effectively, and that we enable world-class science. As Director of Scientific Translation, I focus on the scientific agenda by identifying and

of the Crick?

Our core mission is to discover the biology underlying human health.

The title of our strategy, Discovery Without Boundaries, reflects our intention to maximise permeability across a number of boundaries,

‘Accelerating translation for health and wealth’ is one of the Crick’s five strategic priorities.’

developing translatable science. both internal and external to the ‘Accelerating translation for health institute. and wealth’ is one of the Crick’s five strategic priorities.

The Crick won’t be just a biomedical research institute. It will be The UK has world-class basic multi-disciplinary, with chemistry, science - with 1% of the world’s physics, engineering, mathematics, population we produce almost 15% computing and also clinical and of highly-cited papers - but we need industrial science at its heart: A to improve the translation of this blend of different abilities and research into health and wealth expertise applied to that central benefits.

(Continued on page 6)

6

Member News

Autumn 2015

David Roblin, Chief Operating Officer and Director of Scientific

Translation at the Crick

Crick’s interdisciplinary approach to science.

and the collaborative nature of the Crick itself.

There are lots of discussions underway to develop new collaborations, and we intend to establish a range of different relationships, particularly with others that offer capabilities and expertise that we don’t have within the Crick. This will include the venture community, biotech, and big pharma.

Over the summer, we held a series of genetic engineering workshops for A-Level and BTEC students. The Crick’s public engagement team also took part in a number of events and worked with our partners and the local community on a project to celebrate the UN International Year of Light.

We have recently established an exciting new open science collaboration with GSK, the UK’s largest healthcare company. Using a new model for scientific interaction, Crick and GSK scientists will work question of understanding human side-by-side on projects at both pathophysiology. Our aim is to the new Crick Laboratory and at translate our research to bring GSK’s R&D hub in Stevenage. By benefits to patients and generate embedding industrial scientists economic opportunities for the within collaborating laboratories UK, and we will intentionally place and fully integrated within the groups from different disciplines Crick as a whole, we will accelerate next to each other to encourage breakthroughs in the understanding interdisciplinary collaborations in an of human health and disease. informal way.

‘The Crick’s founding partners are six of the world’s most influential and respected scientific organisations:’ We also have a role to play in creating future science leaders who will then move on to other institutes and universities. Lastly, we aim to make science more accessible to the public, and our building and central London location provide superb opportunities to do so.

Collaborations are clearly important. How will they work and how can others get involved?

The Crick’s founding partners are six of the world’s most influential and respected scientific organisations: Cancer Research UK, Medical Research Council, Wellcome Trust, UCL (University College London), King’s College London and Imperial College London.

This unprecedented collaboration will be vital to the success of the

In keeping with our vision of openness in research, all results from the collaboration with GSK will be jointly published in peerreviewed journals. This will enable important discoveries to be shared with the research community as quickly as possible, maximising the potential for the collaboration to advance scientific understanding and accelerate the development of treatments for patients.

What are you doing to encourage public and local engagement in what is a very high profile project?

We have a unique opportunity to engage audiences with biomedical research, through virtue of our location, the reputation of our founding institutions and partners,

We are continuing to develop programmes to engage both the local community and the wider public with our work. We will seek to increase participation in STEM (Science, Technology, Engineering, Mathematics) and raise levels of scientific literacy, particularly in the London Borough of Camden, which is where the new Crick Laboratory is located.

The new Crick Laboratory is due to open in 2016 – how is it progressing?

We are currently in the final stages of constructing the new Crick Laboratory. The fabric of the building is almost complete and our focus is beginning to move towards commissioning (the phase where we prepare and test building services such as heating and ventilation, energy supplies and building control systems). It is an extremely complex building and has been designed and built to a demanding technical specification to enable outstanding science.

Though the new Crick Laboratory doesn’t officially open until next year, it will reach near capacity in 2019. There’s a lot to do to deliver this once-in-a-lifetime opportunity to change the way British science is undertaken and more effectively translated. I’m honoured to be here at the start of the journey.

Member News

Autumn 2015

7

Synexus’ North East Clinical Research Centre Celebrates One Year Anniversary Synexus celebrates a successful first year with

Northumbria Healthcare NHS Foundation Trust.

us and expressing their interest in participating in clinical research.

We look forward to continuing our success further in the coming year.

Together we can help improve the health of future generations.’

In July this year, Synexus’ North East Clinical Research Centre in Hexham celebrated its one year anniversary. Synexus is the world’s largest multinational company dedicated to the successful recruitment and running of clinical studies, and one year ago with Northumbria Healthcare NHS Foundation Trust, jointly opened the North East Clinical Research Centre at Hexham General Hospital.

In its first year the North East Clinical Research Centre has gone from strength to strength and has been visited 3,750 times by local patients, a number of whom have been successfully enrolled

In addition, GPs in the North East have welcomed the opportunity to contribute to Synexus’ clinical studies and have also been helping identify suitable patients and informing them about the studies in a similar way. Synexus is currently working with 19 GP surgeries in the area to recruit patients in this way.

Kathryn Creighton, Centre Manager of Synexus’ North East Clinical Research Centre, commented ‘We are the first private organisation to conduct clinical research in the North East and in our first year we have been overwhelmed by the support we have received from local patients and their willingness to take part in our research, especially given that many of them travel some way to visit the centre. In the year since we opened we have over 2,500 local patients on our database thanks to them contacting

A recent film shot at the both the Hexham and Manchester sites give a patient’s perspective and an insight into the success - http:// threemotion.vzaar.me/2034161 To find out more about Synexus UK, please contact richard.smith@ synexus.com

Professor Richard Walker, Clinical Director of R&D at Northumbria Healthcare

By sharing services, skills and access to patients over the last year Synexus and Northumbria Healthcare have helped forge a successful partnership and it is hoped that this type of partnership between the NHS and private companies such as Synexus, will be replicated across the UK so that even more patients can benefit.

Northumbria Healthcare has supported six of Synexus’ clinical studies so far through identifying and informing potentially eligible patients about the studies. One fifth of the total patients that Synexus has enrolled onto studies at the North East Clinical Research Centre have been identified in this way.

NHS Foundation Trust with Sarah Beeby, MD of Synexus UK

The partnership is very exciting for UK clinical research as it is the first of its kind between a private company and the NHS and potentially signals a new way of working for the clinical trials sector, enabling UK patient’s access to new treatments and the UK clinical trials industry to remain competitive on the global stage.

Chris Price, consultant physician at Northumbria Healthcare, said: ‘Our partnership with Synexus has had a successful first year and we are very grateful for the support we have had from local patients and their families. As part of Northumbria Healthcare’s commitment towards improving the treatments available onto various clinical studies in the in the NHS, we look forward to following therapy areas - cholesterol creating more opportunities for our lowering, cardiovascular, diabetes, patients to take part in clinical trials irritable bowel syndrome, psoriasis should they wish to.’ and an ostomy pouch system.

8

Member News

Autumn 2015

Cambridge New Therapeutics Forum The purpose of Cambridge New Therapeutics Forum (CamNTF) is a scientific forum open to all scientists interested in research and development of new therapeutics in Cambridge and the local area, including scientists at the University, Addenbrooke’s Hospital, pharmaceutical companies, biotechs, CROs, and not-for-profit organisations.

The purpose of the forum is to promote interactions between scientists at these organisations in order to improve opportunities

for biotechnology research and development.

Location: Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge Biomedical Campus, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE

CamNTF hosts early-evening meetings open to all scientists interested in research into new therapeutics. These rotate around To register visit http://www. different organisations located in onenucleus.com/cambridge-newthe Cambridge biotech cluster. Each therapeutics-forum two-hour session begins with two short scientific presentations and followed by networking and snacks (18.00 - 20.00).

Next meeting: Date: 8 December 2015

Pushing the Boundaries of Science at AstraZeneca

AstraZeneca has long been known for its collaborative and innovative partnering approaches across all phases of drug discovery and development. The company’s innovative collaborations with the University of Cambridge, Medical Research Council (MRC) and Cancer Research UK Cambridge Institute (CRUK CI), as well as its plans for a new Global R&D Centre (image opposite) within the Cambridge Biomedical Campus, provide just a few examples of how AstraZeneca is setting new standards in working with external scientists. ’At AstraZeneca, we believe that scientific innovation and great collaboration go hand in hand,’ says Kumar Srinivasan, VP of Scientific Partnering & Alliances within AstraZeneca’s Innovative Medicines and Early Development (IMED) Biotech Unit. ‘The OI initiative is an effective tool that connects AstraZeneca and global scientific community and enables us

Artist impression

AstraZeneca’s partnering and Open Innovation initiatives raise the bar with new ways of working with academia

to explore additional collaborations that were not accessible through traditional means.’

The IMED has more than 300 collaborations with academic institutions and biopharmaceutical companies.

IMED leads the way in open collaboration As part of AstraZeneca’s commitment to partner more openly, the IMED Biotech Unit has created an ambitious Open Innovation programme. Last year, an Open Innovation web portal was launched to make it easier for

researchers to access a full range of collaborative possibilities, receive feedback on their proposals and connect with IMED scientist to discuss their interests.

In the short time since its launch, the Open Innovation web portal has generated 19 externally sponsored collaborative research Ph 2a studies, more than 100 disease mechanism exploring translational preclinical studies, 26 new target validation and/or screening for lead matter collaborations, more than ten new compound library partnerships, and crowd sourced innovative solutions to ten posted R&D Challenges.

Member News

Autumn 2015

9

and/or clinical projects. We are excited that the second round of this partnership has included additional companies and compounds,’ says Jane Escott, Associate Director and AstraZeneca Alliance Manager for the on-going MRC Industry Asset Sharing programme.

‘Opening our state-of-the-art high through screening facility and compound libraries to basic scientists worldwide has elicited open collaborations with outstanding scientists on truly novel targets. We anticipate the involvement of the MRC will further enhance the quality and novelty of these projects,’ says Garry Pairaudeau, Senior Director and Head of External Sciences, ‘The quality of proposals and, and/or access to HTS compound IMED Discovery Sciences. consequently, our approval rate has libraries to help validate a novel Why create an open research been even better than expected. target idea. environment?

By reviewing the information on • New Molecule Profiling: the web portal and/or interacting AstraZeneca focuses its early stage sophisticated cheminformatics with an AstraZeneca scientist, drug discovery pipeline on highly and screening technologies investigators appear to be selfvalidated targets with a clear lineto explore the properties and selecting as well as framing of-sight to differentiated clinical therapeutic potential of novel their proposals to our interests/ efficacy in focus disease areas. compounds. objectives,’ says Craig Wegner, There is a growing emphasis on Executive Director and Lead for • R&D Challenges: cash awards translational research in many AstraZeneca’s Open Innovation for the best crowd sourced academic institutions and among program. solutions to specific R&D research funding organisations, with hurdles; reductions to practice some academic research institutes Through the web portal, scientists grants often follow. also incorporating screening and and medical researchers can access: lead discovery. By sharing tools, • Suggestion Box: path for • Clinical Compound Bank: technologies, know-how, disease submitting a proposal, idea or compounds with clinical insight and expertise, companies technology that fits outside the data made available for the and academic investigators can test categories above. collaborative pursuit of novel hypotheses (e.g., indications, novel clinical and translational Partnerships with the MRC allow UK molecular targets) that otherwise research proposals. investigators to apply for additional might not be advanced.

• Pharmacology Toolbox: compounds with optimised pharmacological properties for preclinical research to explore novel disease biology and pathways.

• Target Innovation: small grants

support for projects through the new MRC-Industry Asset Sharing Initiative and AstraZeneca-MRC UK Centre for Lead Discovery.

‘Our ground-breaking Mechanisms of Disease partnership with the MRC has yielded 15 innovative preclinical

10

Member News

Autumn 2015

A Transformed Granta Park Plan for the new amenities building at Granta Park

nature walks. BioMed Realty’s vision is for the facility to set the bar for a high quality amenity package that will compete with all science parks in Cambridge and the rest of East Anglia.

The past year has been eventful for Granta Park and its owners BioMed Realty. The life science real estate specialist is expanding the campus and further developing its long-term relationships with its occupiers, including Illumina, one of the most dynamic global biotechnology companies. The campus has new pre-let developments totalling almost 250,000 square feet of additional laboratory and office space. Even more exciting for the existing occupants and larger research community, is the announcement of a new, state

of the art amenities building that expects to open in the spring of 2017.

The facility will house a café, juice bar, as well as a new gym; complete with multiple classrooms for yoga, Pilates, Zumba, spinning, and new equipment throughout.

It will also include a swimming pool, tennis courts, squash courts, and a climbing wall. Nestled at the heart of the campus, the facility will have strong links to the natural surroundings with connections to various foot and cycle paths, including one of Granta Park’s three

This new facility will create an environment for Granta Park’s research community to enjoy and unwind. Its design will allow for a variety of opportunities for people to meet and interact; and hopefully spur creative collaborations and drive innovation.

Douglass Cuff, Director of Granta Park, said, ‘Granta Park is much more than just a science park; it is truly a place that is centered on cutting-edge science and, at its heart, its world-renowned scientists.

BioMed Realty continues to invest in Granta Park and the Cambridge community by offering a live, work and play environment with great amenities.’

MedImmune Collaborates with Inovio Pharmaceuticals In August MedImmune, the global biologics research and development arm of AstraZeneca, entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.

MedImmune intends to study INO3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers.

Emerging evidence suggests that the benefits from immunooncology molecules, such as those in MedImmune’s portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumour-specific T-cells. MedImmune and Inovio will develop up to two additional DNAbased cancer vaccine products not included in Inovio’s current product pipeline, which MedImmune will have the exclusive rights to develop and commercialise.

Under the agreement, MedImmune acquired exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16and 18-driven tumours. These HPV David Berman, Senior Vice types are responsible for more than President and Head of the 70 per cent of cervical pre-cancers Oncology Innovative Medicines and cancers.

unit, MedImmune, said: ‘Today’s collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigenspecific T-cell responses. The unique combination of our broad immunooncology portfolio with Inovio’s T-cell-activating INO-3112, which enhances cancer specific killer T-cells, has the potential to deliver real clinical benefits for patients.’

The agreement builds on the existing partnership between Inovio and MedImmune on two research and development collaborations in the infectious disease area.

Member News

Autumn 2015

11

UK and Swiss Life Science Ecosystems – Undeniably Similar June 2015:One Nucleus/Swiss meeting

conducting research there.

During their keynote presentations, Bertrand Ducrey, CEO of Debiopharm International (Switzerland) and David Williams, CEO of Discuva (UK) shared their vision of the complementarities between the two countries. They also shared concrete examples of ongoing collaborations, meeting with great interest from the audience.

On 10 June, One Nucleus and the Swiss Business Hub UK - the trade and investment promotion department of the Embassy of Switzerland in the UK co-organised a networking event with the aim to foster business and R&D collaborations between Swiss companies and ON members.

an introduction and fascinating insights into the Swiss Life Science environment. Alongside chemical and pharmaceutical corporations such as Novartis, Roche, and Syngenta, the ecosystem consists of a dense network of medical technology, biotechnology and nanotechnology companies.

With discussions focused on drug delivery and drug development, the event demonstrated undeniable convergences: density of key global players and SMEs, academic excellence and most crucially an entrepreneurial ecosystem focused on delivering translational research, efficiently taking new products to the market to improve patients’ lives.

Ambassador Furgler took the audience on a journey of the sector from the Swiss perspective and explored the distinct international focus of the industry. With 98% of sales generated abroad, chemicalpharmaceutical products make up 40% of Swiss product exports, making them Switzerland’s most exported class of goods. The country has many highly-skilled scientists thanks to its position as an international leader among universities and the many wellfunded pharmaceutical companies

After the networking breakfast the Ambassador of Switzerland to the UK, Dominik Furgler, gave

Pitching sessions followed, giving a platform to 13 Swiss and UK companies to present their work and reach out to potential partners.

Amongst them were: Sophia Genetics, Aptus Clinical, ArisGen SA, Antikor, Biolingus Global Regulatory Services, Ethimedix, Isogenica, Hanseler Pharma, Lonza, SpiroChem, Transpharmation and Zuhlke Engineering.

The event was a great success and perfect example of excellent partnerships.

For more information about the Swiss life science ecosystems and landscapes, and for guidance regarding business and R&D partnership opportunities, please contact the Swiss Business Hub UK: lon.sbhuk@eda.admin.ch

What China Means For Business Today The China-Britain Business Council (CBBC) firmly believes that every UK company should consider what China means for their business today. With so many exciting opportunities in and with China, a new wave of engagement by UK companies of all sizes and sectors is being seen. Furthermore, this

is a key time for UK business with an increasing alignment between China’s needs and what UK businesses can provide.

The products and services that China, Chinese businesses and Chinese consumers need at home and abroad are the core

strengths of UK business: advanced manufacturing, creative industries, technology and know-how, retail, financial and professional services, education, and healthcare. CBBC expects opportunities for British companies to arise in fields such as intelligent manufacturing, industrial automation, energy and the (Continued on page 12)

12

Member News

Autumn 2015 • Recognise the value of relationships - build credentials and trust by utilising contacts and developing a support network.

• Recognise China is not one single national market understand the regional complexity and develop a proper China strategy.

The CBBC is the leading organisation helping UK companies grow and develop their business in China. It offers practical in-market environment, ICT, internet finance, membership programme provide UK assistance, services, industry data analysis and safety control. companies with tailored assistance initiatives and a membership in dealing with these challenges. programme delivering access, While the opportunities are vast, CBBC appreciates the challenges Generally speaking, CBBC offers the seminars and networking, for of doing business in China, as with following initial advice to companies further information visit www.cbbc. org any foreign market. Common issues doing business in China: include: finding the right partners; • Do your homework through choosing the right city or region; market research and due and navigating regulations and diligence and make sure your local bureaucracy. CBBC’s business activities are sufficiently funded services, industry initiatives and

14M Genomics - Helping to Improve the Lives of Cancer Patients Dr Alan Schafer, CEO 14M Genomics

art sequencing and analytical tools, coupled with an in-depth understanding of cancer biology, to reveal associations between tumour genomics and the clinical path of individual patients.

It is a transformational period in science as the role of genetics in health and disease becomes better understood. 14M Genomics is working with world leaders in the field to help improve the lives of cancer patients, and over the past six months has announced 14M Genomics is a Cambridgetwo important collaborations: based cancer diagnostic company, the first in February 2015 with working in partnership with the the Haematological Malignancy Wellcome Trust Sanger Institute, Research Network (HMRN) which is and financed by Syncona, a aimed at improving diagnostic and healthcare investment fund of the clinical care pathways for patients Wellcome Trust. The company’s mission is to become the European with blood and lymphatic cancers, and the second in March 2015 leader in the provision of clinical genomics services for the diagnosis, with the European Organisation for Research and Treatment of Cancer treatment and surveillance of (EORTC) where genomic diagnostic cancer. It employs state-of-the-

profiles are being used to facilitate enrolment into cancer clinical trials.

14M Genomics expects to announce a number of similar collaborations over the coming months, focusing on specific cancers where the company’s technology could have a profound impact on diagnosis and treatment.

The company has built a very experienced team which was recently strengthened by the recruitment of Dr Alan Schafer as Chief Executive Officer, bringing extensive experience in research, in big pharma and biotechnology management, as well as in building new businesses.

For further information visit: www.14mg.co.uk

Member News

Autumn 2015

13

European Mediscience Awards 2015: One Nucleus Official Supporter One Nucleus and Bionow at the European Mediscience Awards

Brophy, Probiodrug AV for Best Technology Award sponsored by Life Sciences Partners, the FT’s Andrew Ward for the Mediscience Commentator of the Year sponsored

by Instinctif Partners, Valneva SE for the Capital Market Transaction of the Year Award sponsored by Euronext, Jan van de Winkel from Genmab A/S won the Chief Executive of the Year Award sponsored by Panmure Gordon & Co, Immunocore Ltd won the Emerging Star Award sponsored

by Peel Hunt and finally, Cellectis SA won the coveted Company of the Year Award sponsored by Canaccord Genuity.

This year, the annual European Mediscience Awards had a very distinctive buzz in the air. It has been a very active year for the healthcare community, with numerous mergers, consolidations, IPOs and drug developments taking place. Therefore an event that celebrates achievement in the industry was an event not to be missed!

made an impact or has demonstrated significance within the sector. Voting takes place confidentially and anonymously and the winners are revealed at the event, which this year took place in a stunning setting at the Tower of London.

Brian White, Head of Healthcare, Shore Capital and Dan Mahony, Polar Capital Holdings

One of the most popular winners this year was Polar Capital’s Dan Mahony, who was awarded the Most Significant The European Mediscience Awards is Contribution to the Mediscience Sector the largest annual gathering of private Award, sponsored by Shore Capital. and publicly quoted healthcare, life Having worked for a Biotech company science and biotech companies in in the 90’s, Mahony is also a former Europe. The main sponsor is Dutch scientist, therefore his knowledge and Investment Bank, Kempen & Co. and expertise are incredibly vast, making it has grown year-on-year to become him a formidable contender in this an essential event for those looking category. Dan was incredibly honoured to make relevant new contacts and to win the award and told us, ‘Being to reconnect with existing ones. The nominated in this category made me core of the evening is dedicated to feel very humble, therefore to win rewarding the industry successes was a real honour. It helps highlight that have taken place throughout the what Polar Capital is achieving in year; a celebratory feel is very much the market and demonstrates the evident and ensures attendees return expertise we have within our team. year after year.

Winning an award sets us apart from our competitors and proves we are With a total of nine awards, presented leading the field within investment

by BBC presenter, Louise Minchin, management.’ the awards pick out key individuals and companies that have genuinely Other winners on the evening, made a difference. A voting panel of include Galapagos NV for the Best well known, established life science Communication Award sponsored by analysts and industry watchers attend Consilium Strategic Communications, a meeting prior to the event to discuss Bavarian Nordic AS for Breakthrough and debate who they believe has of the Year sponsored by Hume

It remains to be seen who will be nominated and scoop awards next year, but planning has already begun and with the current market climate set to continue, we anticipate another hugely successful year ahead. A new home for the awards has been secured at The Brewery, EC1, to accommodate an increase in attendees. For further information on the awards, please contact jo.thomas@ford-sinclair.co.uk

14

Member News

Autumn 2015

An Active and Productive Year for Domainex a unique approach to pursuing targets implicated in a range of human diseases including cancer, respiratory, cardiovascular, and immune-inflammatory conditions.

Domainex’s internal pipeline continues to make good progress.

The IKK epsilon project for inflammation (COPD) received a Bio Catalyst grant from Innovate UK which will allow progression to IND-ready status. This project has now shown activity in disease models and is approaching candidate selection. Domainex’s is also utilising its core platform technologies to develop and impressive early discovery pipeline focussed on the lysine methyltransferase (KMTs) class of The last year has been a highly The year has also seen the launch active and productive one for of a number of technology initiatives targets in epigenetics. Determining the crystal structure of a number Domainex seeing the company including BioassayBuilder, a new of KMTs is proving extremely useful advance on several fronts including platform that expands on existing some significant corporate changes. protein expression, hit identification for the design of inhibitors which are both soluble and non-toxic. This Dr Tom Mander joined as Chief and medicinal chemistry services. portfolio will be increased in the Operating Officer with the remit of BioassayBuilder draws on the near future with an additional grant running Domainex’s service division extensive expertise of biologists awarded by Innovate UK. alongside the appointment of Barry at Domainex over a wide range of Knight as Chief Financial Officer to druggable gene families that include Domainex is anticipating strategically manage the financial protein-protein, enzyme, epigenetic another strong year with further development of the company as and GPCR targets. Coupled to opportunities for new contracts and it grows and expands. Several the proprietary Combinatorial for strategic growth. new collaborations have also been Domain Hunting technology for announced with academic groups unlocking difficult to express protein and Biotechs such as Forma and targets, and LeadBuilder for hit Auspherix. identification, BioassayBuilder is

The Science and Business of Rare Disease rare disease. They affect more than 3.5 million people in the UK alone.

How can we ‘bridge the gap’ to bring discoveries from the lab to the clinic sooner?

And how can we ensure that the voices of patients and carers are central in rare disease research?

With more than 6000 rare diseases already identified, we each face a one in 17 chance of developing a

saw scientists, investors, clinicians, policy-makers, patients and carers sharing their insights into the current initiatives and unmet needs around rare diseases.

The morning programme focused on funding and investment, with a panel featuring heavyweights of the Cambridge biotech scene Nearly 200 people from across the followed by a discussion of alternate UK and abroad came together in funding strategies: not-for-profit Cambridge this month to discuss pharmaceutical companies, social the opportunities and challenges in impact bonds, and non-financial rare disease research. The inaugural incentives for drug development.

Cambridge Rare Disease Summit

Member News The afternoon was a whirlwind tour of the latest in rare disease: from the 100K Genome Project, to engaging with pharmaceutical companies, to the RareConnect patient support network. Coffee breaks buzzed as collaborations were formed and advice was swapped.

Autumn 2015

15

disease advocate, brought home the very personal struggles faced by people with rare disease and the impact that research can have on the lives of individuals.

seeking to unite the Cambridge rare disease community, building on the region’s strengths in research and biotechnology for the benefit of people with rare diseases.

The event was jointly hosted by the Cambridge Rare Disease Network and FindACure, two new groups

For more information: http:// camraredisease.org/ and http:// www.findacure.org.uk/ CRD Summit

A real feature of this summit was the strong presence of patients, parents and carers, starting with US parent advocate Dr Matt Might’s opening keynote. He shared his experience as a father who was told nothing could be done for his son, who was diagnosed with the rare disease NGLY1, and his journey to build a community to advocate for treatments and cures. His message was that there is always one option: to do science.

A closing video message from Proffessor Stephen Hawking, Cambridge’s best-known rare

New Base and New COO for PhoreMost Jeff Roix, Chief Operating Officer at PhoreMost

The benefits of being at Babraham are already evident, as PhoreMost has started collaborations with a number of on-site companies, such as Sphere Fluidics, who have developed a next generation microfluidics-based cell-sorting instrument that will significantly increase the flexibility and functionality of performing highthroughput phenotypic assays.

PhoreMost is focused on increasing the diversity and affordability of novel targeted therapies, by systematically identifying new druggable targets. While great It has been a busy few months for advances have been made in new-model drug discovery company, understanding the causes of many PhoreMost. In August the company diseases, such as cancer, most relocated from the Cambridge disease genes remain frustratingly Science Park to the Babraham intractable to current drug discovery Research Campus. This move has technologies. PhoreMost is aiming enabled access to campus services to remove these barriers to new and shared scientific facilities, both drug development with its novel of which are hugely important to SiteSeeker technology, a live-cell PhoreMost as the company is rapidly phenotypic assay system that can growing. rapidly identify unexpected, or

cryptic druggable sites in disease driving targets and pathways that can’t be readily seen using conventional non-cell based analytical methods.

The company’s approach is garnering early interest for collaborations from the pharmaceutical industry.

In February, PhoreMost appointed a new Chief Operating Officer, Jeff Roix. A career biologist, Jeff previously held senior associate positions at BioMed Valley Discoveries, Constellation Pharmaceuticals and Novartis. He has a degree in Biology from the Harvard Extension School.

16

Member News

Autumn 2015

Continued Growth and Investment for Horizon Discovery Dr Darrin M Disley, CEO and President, Horizon Discovery Group

• Expansion of sales channels for reagent products through Original Equipment Manufacturing (OEM) partnerships with ArcherDX, CareDx and Transgenomic, and through the supply of genomic standards to Cancer Research UK. • Supply and commercialisation agreement with Thermo Fisher Scientific, establishing a new high-value sales channel for Horizon’s X-MAN cell line catalogue, providing significantly greater market reach through Thermo’s extensive eCommerce and direct sales channels into the academic market.

• Expansion in the cell line and diagnostic reagent inventory to in excess of 20,000 catalogue products.

• Launch of multiple new high value products including IHC reference standards and rapid on-demand knockout cell line generation.

Dr Darrin M Disley, CEO and President, Horizon Discovery Group plc, commented: ‘Horizon’s story of growth, providing high value products and services to our customers, and scientific leadership has continued on pace The past few months have seen throughout 2015. We have seen Horizon Discovery continue to particular success in developing leverage its proprietary gene key relationships that have the editing, cell line and drug discovery • Horizon entered into a cancer potential to deliver significant long technology platforms and expertise. collaboration with Redx Pharma term scale for the business, and in Some highlights include: to progress Redx’s pan-RAF providing integrated solutions to inhibitor programme with the customers engaged in translational • Horizon signed a license and potential for considerable future research and personalised medicine supply agreement with Abcam milestone and royalty payments. development from DNA sequence to plc, providing exclusive access patient treatment.’ to over 1,800 human diploid • Continued innovation and and haploid cell line models investment in R&D leading from Horizon’s X-MAN collection to the launch of new nextfor the functional validation generation services in line with of Abcam’s monoclonal and customer demand, including polyclonal antibody catalogue.

CRISPR-Cas9 genomic screening

Life Science Leadership Series Chesterford Research Park, Cambridge, UK

Respiratory and Inflammation 11 February 2016

Please visit the link below to register: onenucleus.com/onenucleus-events

Member News

Autumn 2015

17

Healthcare Pioneers Receive National Support to Roll-Out Innovative Technologies Dr Peter Young

Dr Maryanne Mariyaselvam

and abroad identified to receive national support to roll out their technologies, processes and models of care to patients, hospitals and GP practices throughout England.

Through the fellowship, each will receive mentorship from seasoned innovators such as Lord Ara Darzi, a bursary, and support to spread these new ways of working across the country.

Dr Mariyaselvam’s innovation, the Non-Injectable Arterial Connector (NIC), will improve the safety and care of all patients requiring an arterial line in operating theatres and intensive care.

Drs Maryanne Mariyaselvam and Peter Young of Queen Elizabeth Hospitals Kings Lynn (QEHKL), both inventors of technologies originally progressed with support from Health Enterprise East (HEE), were congratulated recently on becoming fellows of the NHS Innovation Accelerator (NIA) programme.

The scheme, announced in July by Sir Bruce Keogh, NHS England’s Medical Director, sets out to get evidenced healthcare innovations adopted at scale and pace nationally, ultimately making them more widely available to patients.

QEHKL is a HEE Member Trust with HEE assisting in the development of both the projects.

Dr Mariyaselvam and Dr Young join a prestigious group of 17 healthcare pioneers from the UK

Dr Young’s innovation, the PneuX Pneumonia Prevention System, is designed to stop ventilatorassociated pneumonia (VAP), the leading cause of hospital-acquired mortality in intensive care units.

In a joint comment Drs Mariyaselvam and Young said, ‘Innovation should be at the heart of the NHS, as should mechanisms for spreading innovative solutions to patients quickly and effectively.

We are delighted that both technologies have been selected for the NIA programme and with the support of NHS England, we look forward to seeing them scaled and implemented nationally across the NHS. As a Member Trust, QEHKL is thankful to HEE for its help in the development of the projects to date and in reaching this significant milestone.’

‘This is great news from one of our Members Trust and we pass on our sincerest congratulations to Maryanne and Peter on being awarded NIA fellowships,’ commented Stuart Thomson, Commercialisation Director, HEE. ‘Having worked closely with the inventors, clinical team and QEH on these and other projects, we are delighted that both innovations will be receiving NHS England support for national roll out in order to deliver significant and wide reaching patient benefit.’

For more information visit www.hee. org.uk

Top Tier for Patents and Trade Marks D Young & Co has recently joined as a One Nucleus member, but the London and Southampton based intellectual property law firm has been working in the life sciences sector for well over 30 years (and

in fact has been in business for well over a hundred years). D Young & Co has a proud history of supporting pioneering companies, from spinouts and SMEs to multinationals, enabling them to protect their

inventions, technologies and brands on a worldwide basis.

Last month the firm announced that it has again been ranked by Legal 500 as a top tier patent and (Continued on page 18)

18

Member News

trade mark firm. Legal 500 conducts extensive research each year in order to profile UK firms with a view to including them in their directory, noting that ‘every firm ranked – and every individual mentioned – in The Legal 500 UK is recommended’.

This means that D Young & Co can continue to be ranked as a top tier UK IP firm by all the independent UK directories (Legal 500, Managing IP, IAM Patent 1000, World Trademark Review 1000 and Chambers).

Unlike many traditional law firms, D Young & Co is a ‘legal disciplinary practice’ (LDP) – which means it is able to bring together the specialist services of patent and

Autumn 2015 trade mark attorneys with those equally specialist services of IP solicitors. Legal advisors are also specialists in their respective technologies and sectors, covering a diverse range of scientific fields, including biotechnology, chemistry, pharmaceuticals, electronics, mechanical engineering, IT and many more. The overall aim is to create a client-focused ‘IP centre of excellence’– giving client’s access to a full range of IP-related services, under one roof.

across continental Europe, the US and Japan. With this diverse and multinational client base, clients can expect sound commercial advice from experienced practitioners.

D Young & Co host a quarterly biotech patent case law webinar, which provides a helpful and concise presentation of topical cases in the industry. If you would like to receive an invitation for the next webinar, please email registrations@dyoung. com

As well as serving clients from all over the UK, D Young & Co advises leading pharmaceutical, chemical and biotechnology companies

Celebrating 5 Years Supporting Life Science Companies Lorna Cuddon, Zyme’s Managing Director

Positioning itself as providing a fresh approach, Zyme’s experienced team has the flexibility to support projects of all sizes, ranging from single press releases right through to fully integrated marketing communications programmes involving strategy and planning, branding, digital, design and development.

Having celebrated its 5th birthday in June, Zyme Communications is looking forward to building on strong foundations, providing specialist, global life science communications support to companies from small, local startups to large multi-nationals.

‘We are excited to be having a milestone birthday and extremely proud of what we have achieved for our clients. When we started out in 2010, we had just a handful

With offices in Cambridge and Manchester in the UK, and with a network of partners in Europe and the US, Zyme is focused on providing PR and marketing support that delivers real value. With an objective-led approach Zyme Communications continues to go from strength to strength.

of projects and now five years on we work with over 50 companies and provide media support for a range of industry leading events,’ commented Lorna Cuddon, Zyme’s For more information please email Managing Director. ‘We thoroughly info@zymecommunications.com or enjoy working with such a wide visit www.zymecommunications.com variety of organisations, and gain real satisfaction from helping them to raise their profile, build corporate value and generate interest from commercial leads, investors and partners.’

Member News

Autumn 2015

19

DefiniGEN Licences Technology from University of Cambridge Dr Marcus Yeo, CEO of DifiniGEN

DefiniGEN has strengthened its IP portfolio with a licence

for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimised cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis. The technology, licensed to DefiniGEN by Cambridge Enterprise, uses induced pluripotent stem cells, or iPS cells, to recreate embryonic lung development in the lab by activating a process known as gastrulation, in which the cells form distinct layers, from which the lung ‘grows’. Uniquely, the technology enables these cells to develop further, into distal airway tissue, which is the part of the lung

responsible for gas exchange and is often implicated in disease, such as cystic fibrosis, some forms of lung cancer and emphysema.

Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN, said: ‘This license enables us to use stem cells to grow highly functional lung cells on an industrial-scale for the first time. These cell products can then help researchers to elucidate key mechanisms of disease and enable pharmaceutical companies to screen for potential drugs in a reproducible and costeffective way.’

One Nucleus Key Partner in Successful Launch of The Case for Cambridge The essence of the message to Whitehall is that Cambridge has a dynamic economy and a proven track record of high value, accelerated growth, and is unique in its importance to the UK economy.

Its exceptional characteristics make it a leader in the development of prosperity for the whole of the • Local GVA per capita is 34% UK. But the city is at a crossroads higher than the national − poised for the next wave of average. growth but held back by a need for infrastructure investment. The • Cambridge is one of the few initiative outlines five key asks to cities making a net contribution Government to enable the city to to the UK Treasury.

The Case for Cambridge is begin this next period of growth.

• Cambridge has nearly nine times an initiative aimed at central Key facts about Cambridge the number of patents per head Government to convince ministers of the average of the next nine of the urgent need for investment in • Cambridge has developed an highest cities in the UK. infrastructure, housing and skills to outstanding record of business ensure the city’s continued growth. success, based on a symbiotic • More than 25 of the world’s As well as ourselves, the Partnership relationship between a worldlargest corporations have includes ten other key organisations leading University and one of established operations in the from Cambridge, including Europe’s top technology clusters city.

Cambridge Ahead, the University, (Continued on page 20)

Alex Plant, Chair of Cambridge Ahead Transport Project and Programme Director, Market Reform and

three tiers of Councils and the GCGP Local Enterprise Partnership.

Head of Policy & Regulatory Strategy, Anglian Water talks devolution and public sector finance

Many of our members are based in the Cambridge city region and have been major contributors to the successful growth of the local economy. However, this brings its own set of problems. As the city has grown, so has congestion on the roads, and there is a shortage of housing as well as Grade A office and R&D space. These things threaten to restrict future growth and so One Nucleus was a key driver in the formation of a partnership of business, academic and local government organisations with an agenda to tackle these problems.

20

Member News

• Cambridge unemployment is a quarter of the national average.

• There are over 4,500 knowledge-intensive companies registered within 25 miles of Cambridge. They have grown employment by 7.4% per annum since 2011.

Autumn 2015 • Schools are poorly funded – funding per pupil for Cambridgeshire schools is about £600 less than the English average.

• The paucity of ‘Grade A’ Office and R&D space is a serious constraint to business growth.

• The proportion of local company • There is a shortage of workers employment engaged in with practical and vocational knowledge-intensive activities is workplace skills. exceptional at 30%, compared So, the message to Government with a 12% national average. is that there is a danger that hiHowever… tech companies in the city will expand elsewhere in the world • Public transport is inadequate and the opportunity of creating an with chronic congestion on the advanced economy will be stifled. roads.

The Partnership is already engaging with national Government and we • There is a shortage of housing are optimistic that it will listen. We along with rocketing house are not asking for public money but prices. a framework in which the city can

raise and attract its own investment using innovative funding methods, such as tax increment financing and imaginative funding approaches for local authorities to attract private investors.

The public launch was held at the Cambridge Union Society on Friday 9 October and was attended by over 150 people. As well as four speakers, there was a panel discussion, which included the three city region MPs. View a digital copy of The Case for Cambridge prospectus. http:// www.cambridgeahead.co.uk/wpcontent/uploads/2015/10/CfCProspectus-printable-pdf.pdf

Journalist Priorities and Pet Peeves Revealed at ‘Media Question Time’ BioWednesday how do the journalists prefer to interact with industry? Each journalist was clear that they are interested in compelling, yet simple stories with angles or readacross into wider sector trends.

They also like to get to know the top executives in the life sciences space who can offer them context and industry information. Lunch or coffee meetings are always helpful, provided the journalists can get away from their desks – the 24 hour media and constant demand for content means that many are When it comes to the media, Instinctif Partners, who assembled a having to produce more with less is anything ever really ‘off the panel of five healthcare journalists time. record’? The ‘Media Question Time’ in front of a C-suite audience who BioWednesday on 7 October was quizzed them on the big healthcare Interestingly, on being asked very much ‘on the record’ giving trends, best practice and how to where they source their news and the gathering of senior industry work with the media. The panellists information, each journalist followed executives, who were grilling put through their paces were their industry peers, including leading sector journalists, an expose Andrew Ward of the Financial Times, each other, and relied on respected on the inner workings of the media Peter Evans of The Sunday Times, specialist sector outlets for context and how they like to source their Makiko Kitamura of Bloomberg for their stories. stories.

News, Mike Ward of Informa and And what about the future of Lisa Urquart of EP Vantage.

The event was hosted by business traditional news outlets in the communications consultancy, One of the key questions was, age of social media and self-

Member News

Autumn 2015

21

publication, where anyone can be a commentator? The panel concluded that there would always be a need for reliable and trusted news sources and even paid-for content in what is rapidly becoming an almost anarchic online environment.

– gave his perspective on corporate reputation management, having worked on both sides of the fence.

Tom Sheldon from the Science Media Centre also gave great insight into importance of accurate scientific reporting in the media.

in the US. Any stories sent to them have to be compelling and pitched properly to the right person.

The event was also co-sponsored

by Coulter Partners and brought together around 100 industry professionals for an insightful evening. As well as the interactive panel, one of Instinctif’s exjournalists, Managing Partner, Damian Reece - former Head of Business at Telegraph Media Group

• Twitter is useful for journalists • ‘Off the record’ is very rarely particularly as a temperature ever completely off the record. gauge and sanity check on news An executive shouldn’t say stories, not necessarily as a anything to a journalist that source of corporate news. they wouldn’t want to appear in print.

• Journalists are rapidly

• Executives speaking to the media shouldn’t expect copy approval on quotes or articles, Other topics covered how each Key insights from the event it is important for reporters journalist preferred to be pitched included: to maintain full journalistic to, their use of Twitter as an integrity. Journalists will often • The media is a little like family; information source and pressure check to confirm facts and you can’t choose them, they are gauge and thoughts on how relevant figures and if anything isn’t always going to be there and news embargoes really are in an correct they will endeavour to you shouldn’t ignore them. age of 24-hour international media. correct it as soon as possible.

becoming outnumbered by PR professionals, particularly

Digital Media First Amongst Equals Digital Media has progressed greatly in the four years since First Sight Media first became a Partner of One Nucleus. At that time the concept of communicating via the web was still alien to many.

Today, as a film production company, 95% of video First Sight Media captures is streamed to the web reaching a global e-audience.

Whether it be live interactive webinars, conferences, staff presentations, video for websites - all communicate in a clear and concise format.

First Sight Media is one of the leading suppliers of digital media and works in many markets - both geographically, notably the USA and Europe and across sectors including Life Sciences and healthcare, Finance, Software and Education.

2015 has been a milestone year for First Sight Media when in April, Ede & Ravenscroft acquired a share of the company. Now being part of a £50 million group, First Sight Media is able to further plan for a very bright future and acquiring better equipment and developing new software to join iPresenter (First Being able to interact live with the Sight Media’s unique synchronised Technical Director of a high tech video and PowerPoint presentation). company as they demonstrate a The latest technology is training new product to potential clients; videos with questions after each; the CEO providing a live update users passing the test, then to their staff on the company’s move on to the next video. After performance; a video on the website successfully completing the course, selling the features and benefits of a certificate is instantly printed on an organisation 24 hours a day and the e-viewer’s printer. streaming conferences globally: these are an everyday occurrence A particular highlight of 2015 was in for the team at First Sight Media.

September at the West Oxfordshire Business Awards (WOBA) – which

was where, as Harriet of One Nucleus exclaimed ‘the Prime Minister had the opportunity to meet you Mike!’ One Sight Media provided not just the film production but also the staging and audio visual services – offering the full package and a one stop shop for live events.

Since being nominated for an award First Sight Media has also become heavily involved with WOBA and over the past couple of years has sponsored the Charity Award, producing a video to highlight the winning charities’ efforts.

If you would like to be part of our future please contact: Mike Gilham – 01993 837144 or email mikegilham@firstsightmedia.co.uk website: www.firstsightmedia.co.uk / www.ipresenter.co.uk

22

Member News

Autumn 2015

New Pharma Partner Astex Pharmaceuticals Joins MRC Technology in Dementia Consortium The Dementia Consortium is a unique £3.5m charityprivate partnership, set up as a collaboration between Alzheimer’s Research UK, MRC Technology and the pharmaceutical companies Eisai, Lilly and now Astex. New partner Astex brings not only knowledge and resource, but additional capital investment to help fund projects.

The Consortium hopes that by bringing together their expertise, along with focused investment, they will bridge the gap between academic research and the pharmaceutical industry in the search for drugs that slow the development of neurodegenerative diseases that cause dementia. The Dementia Consortium is open to global research teams and funds robust target validation and early phase drug discovery to accelerate progress through the

translational research pipeline.

Dementia Consortium and we look forward to applying our expertise in To date the Consortium has awarded drug discovery and fragment-based around £800,000 of funding for drug design to this endeavour.’ research projects focusing on Alzheimer’s disease, Amyotrophic Dr Simon Ridley, Director of Lateral Sclerosis (ALS, also Research at Alzheimer’s Research known as motor neurone disease UK, added: ‘We are delighted to or Lou Gehrig’s Disease), and welcome Astex on board, to broaden Frontotemporal Lobar Degeneration ties with industrial partners and (FTLD), the most common cause of bring new perspectives to the dementia in people under the age of Consortium. The collaborative 50. model of the Dementia Consortium brings world leading expertise and Dr Lee Dawson, Vice President of capabilities together, to accelerate CNS at Astex, said: ‘The biologiprogress from academic laboratories cal mechanisms that underpin the across the world into much soughtpathology of dementia are incredibly after treatments in the clinic.’ complex, and new opportunities for possible therapeutic intervention For more information please visit can only be developed by pooling http://www.dementiaconsortium. research knowledge and know-how org/ from across academic, charity and industry sectors. Astex is excited about becoming a partner in the

London’s premier Life Science & Healthcare networking conference

genesis 2015 10 December 2015

QEII Centre,

Westminster, London, UK genesisconference.com Tweet with tags #ongc15

OneNucleus NucleusNews News One

Autumn2015 2015 Autumn

23 23

Genesis Conference Review 2014 and Preview 2015 Harriet Fear speaking at Genesis 2014

• Case study deals – selected by SCRIP Intelligence.

• Empowering technologies – in immunotherapy, NGS & population genetics and antiinfectives.

• International growth – sessions on North America, Europe and Asia-Pacific.

• Nurturing innovation – infrastructure, funding and market access as key drivers.

between academia and industry led

by GSK and the Sanger Institute, took the BioNewsRound award after a very close public vote. Sessions on the role of imaging and cellbased platforms in increasing the efficiency of drug discovery and development were led by Kevin Cox (Imanova) and Stephen Minger (GE Healthcare), respectively. The case study deal sessions shed new light on how to do deals in China, how AstraZeneca came to buy BristolMyers Squibb (BMS) out of their Including the fringe events, of diabetes alliance and the innovative which there were ten covering BMS/F-star Alpha deal. These are topics as diverse as ‘Investing in just some of the highlights from IP’, ‘Leveraging UK and Australia in 2014. You can check the available early clinical development’, ‘Creating slides, picture gallery and videos a 21st century infrastructure for of the whole event at http://www. innovation’ and ‘SPARK 2014’, genesisconference.com/ well in excess of 1,000 delegates Plans for 2015 have been underway engaged with Genesis and the for some time and we are busy surrounding events across in building the programme with a focus London. on stimulating debate and sharing The sessions at Genesis 2014 best practice about the challenges included Mike Ward’s ‘Winners & of ‘Taking Bio-Innovation to a Global Losers’: a roundup of the state of Market’. Preceded by a MedCity the sector providing key thought breakfast briefing, the opening leadership on how to manage and plenary session will mix keynote use big data of differing origins presentations with a panel debate effectively, and how risk-sharing led by the London Stock Exchange. and value-based pricing can work Reflecting the growing appeal of (in theory) to meet the healthGenesis, there will be five parallel economic challenges faced by the leadership streams focussing on the industry. The Centre for Therapeutic following: Target Validation, a consortium We are always keen at One Nucleus to keep our activities fresh, relevant and exciting. With this in mind our Genesis 2014 introduced some new elements, including for the first time the Source Lounge and the Genesis Fringe. We of course retained the very well received plenary session presentations and debates, the break out leadership streams, the exhibition, 1-2-1 partnering and one of our firm favourites, the BioNewsRound Award.

• The Farr Institute of Health Informatics Research annual industry forum.

A new layout to the exhibition hall will provide each exhibitor with greater visibility from the everpopular BioCafe. The BioCafe itself is undergoing an evolution this year thanks to sponsorship from United Airlines, with the introduction of information and photo boards to help delegates to get the most out of the conference agenda and networking opportunities.

The traditional features will remain, of course. This year the Welsh Life Sciences Hub is sponsoring the 1-2-1 partnering facility and UK Trade & Investment’s Life Sciences Organisation is supporting the plenary lunch. The evening before Genesis we shall once more be returning to Canada House for the welcome reception, which will be preceded by a seminar on ‘Smart technologies in patient adherence’ and a showcase of what’s happening in the north-west of the UK from Manchester Science Park and Alderley Park.

Tony Jones, Director of Business Development

24

One Nucleus News

Autumn 2015

ON Helix 2015 Harriet Fear, One Nucleus

alkaptonuria. Farid Bidgoli, from Merck Sharp & Dohme concluded the keynote session. He used his grandmother as an example of how the use of using digital health could have changed some outcomes for her and how by adopting them now and into the future it may help patients in the long term and improve their quality of care.

Our annual ON Helix conference took place this year on 14 July at the newly refurbished Wellcome Trust Conference Centre in Hinxton, Cambridge. With 300 delegates, 30 exhibitors and a comprehensive programme, ON Helix proved again that it is a must attend conference for the life science sector, particularly given its focus on the vital subject of translational research.

The aim of ON Helix is to bring academia and industry together; to bridge the gap between basic research and launching a product onto the market, a part of the drug discovery process that is not focused on at most other conferences around the UK and wider sector.

Proceedings kicked off at EMBL-EBI, Hinxton, the afternoon before the conference, with our the Summer BioNewsRound Award. Nine organisations were shortlisted to present their news stories on the day.

They had to pitch their tale in five minutes, conveying the significance of their news to their organisation, the sector and most importantly the patient. The audience then voted on who should be awarded the coveted title of 2015 Summer BioNewRound Award Winner. Ted Agne, President of Communications Strategy Group Inc and sponsor of the award, announced Abcodia as the winner. Represented

by Mike Fisher, Director of Strategic Alliances, Abcodia presented two press releases about the launch of the company’s ROCA® Test, the world’s

first ovarian cancer screening test, which is now available in the UK. The awards were followed by a vibrant panel debate led by Adrian Dawkes, of PharmaVentures, a new One Nucleus Partner, on publishing data, and the audience then had an in introduction to the Centre for Cellular and Molecular Platforms (C-CAMP), Bangalore, representatives of whom had travelled from India to attend the Ignite programme (Cambridge Judge Business School) and ON Helix, as well as to meet other key leaders in the Cambridge area. One Nucleus signed a strategic partnership with CCAMP earlier this year and it was great to see the collaboration manifesting itself at ON Helix.

And so to the big day. There was a fantastic buzz to it as our guests marvelled at the new shape and design of the Welcome Genome Campus Conference Centre. Bahija Jallal, Executive Vice President of AstraZeneca and Head of MedImmune was our opening Keynote Address.

She gave an insightful summary of the research landscape of drug development, including its challenges and concluded by talking about the use of personalised medicines into the future.

This speech was followed by Nicholas Sireau, CEO of the AKU Society, who captivated the audience with his personal story about the challenges of rare diseases, and discussed the work his charity is doing to find a cure for

The rest of the day was based around very practical and hands on provision and explanation of actual based case studies. Companies presented their experiences and then took part in panel discussions that engaged the audience. The main theme of these sessions was de-risking: what do companies do to de-risk translational research whilst working with other organisations?

The first session discussed de-risking collaborations and was chaired by Professor David Gann from Imperial College London. Professor Sir Philip Cohen spoke from an academic perspective about the work he has done so far with other organisations to bridge gaps in translational research.

Horizon Discovery, European Lead Factory and King’s College London were also part of this lively debate.

The next panel discussed how organisations should share data with one another during collaborations and the importance of material transfer agreements. This was explained superbly by Niall Martin from MISSION Therapeutics. This session also included speakers from the Centre for Therapeutic Target Validation, Babraham Institute and Eli Lilly.

The final session, on de-risking funding in early stages of development, was very lively session with Jane Dancer from F-star chairing. The breadth of the discussion was aided by having a variety of funding bodies represented on the panel, including Alzheimer’s Research UK, SR One, MS Ventures and Cambridge Innovation Capital.

This year, ON Helix captured what the UK does best: early stage translational medicine. It brought academia and industry together

One Nucleus News

Autumn 2015

25

Ice cream refreshments at ON Helix

under one roof, allowing knowledge in the sector to be shared across the fields. The conference provided a great environment for networking, which carried on into the evening at the drinks reception in the beautiful Hinxton Hall. After such a successful event, plans for the next ON Helix are already taking shape. This will be held on 28 June 2016 at the Wellcome Trust Conference Centre, Hinxton.

Nadia Shivji, Events & Business Development Manager

One Nucleus Training So far, 2015 has been an extremely busy year for training at One Nucleus, with as many as 30 training programmes being delivered both in-house and as open courses.

As a Cogent Assured Provider, One Nucleus is able to guide eligible companies through the application process to receive up to 50% reimbursement for the cost of some training courses.

The Science Industry Partnership (SIP) Small Business programme is a Government funded initiative available to small to medium sized companies with less than 250 employees in the science-based industries.

provoking. His style of delivery is one of the best I have experienced and I felt confident in asking questions. I think his approach made the group gel very quickly so we learnt a great deal from each other and were able to be completely honest about what we did, and didn’t, know.’

Presentation Skills for Scientists is one day course that, unlike many presentation skills courses, is designed specifically for the practising scientist. The programme cover all aspects of verbal scientific communication, asking delegates to present their own research in a conference format, prompting feedback on style and content.

Two new courses have been added ‘I found that giving the to the portfolio this year, both of presentations and watching them which have been greatly received by back was extremely beneficial as participants: it highlighted areas of my body language I was previously unaware Understanding Business Finance of.’ is a one day course designed for anyone who wants to understand Do remember that One Nucleus how businesses work financially, members are entitled to discounts from managers controlling a budget on list prices for training courses. through to business leaders wanting Members of the BIA, Bionow and to engage more confidently with CCRA receive a 10% discount off the financial experts within and the non-member rate. supporting their organisation.

‘Peter’s excellent understanding finance workshop was straightforward and thought

All of our courses can be adapted and tailored to meet your needs, and can be delivered cost-effectively

in house. Contact training@ onenucleus.com to find out more.

FEB 17

FEB 23 - 24

Presentation Skills for Scientists

Biological Safety: Management and Practice (2 day course)

FEB 25

A BioSafety Masterclass: Building and Maintaining Competence in BioSafety

MAR 01

Compressed Gases

MAR 07

Introduction to Drug Development – Scientific professionals

MAR 14 - 15

Introduction to Managing Life Science Projects (2 day course)

MAR 16

Introduction to Drug Discovery

26

One Nucleus News

Autumn 2015

Enabling Member Competitiveness in an Increasingly Externalised R&D Landscape plans. Of particular note are:

innovative solutions from 11,000 providers.

Our International linkage: In addition to the established • Tagging as a ‘One Nucleus collaborations with Biocom, member’ for sellers to enhance California Life Sciences Association visibility to the hundreds of (ex BayBio), MassBio and buyers searching.

MassMEDIC in the US and the • Access to pre-qualified buyers Council for European BioRegions to decrease the risk for those across Europe, One Nucleus has selling R&D services. extended its collaborative links across the two continents to include • Use of an invoice and payment BioNJ (New Jersey), PennsylvaniaBio tracking system via the and Life Sciences British Columbia. platform.

There are now a plethora of terms used to describe what is essentially ‘out-sourcing’. Whether called partnering, collaborating, using a CRO/CMO/CDMO, creating a consortium or multi-partner initiative, Open Innovation, or any other term, the result is the same: having external organisations involved in your business. The terminology simply varied to define the business and financial contractual basis of the relationship.

Despite concerns around areas such as IP protection, data quality, cost containment and control that often get aired, the trend is still very much moving towards outsourcing.

Pharma companies accepting that they can’t do everything brilliantly and biotech investors who are encouraging their portfolio companies to be lean and focussed are together providing an immense driving force for change. Moreover, external sources can often do things better, faster and cheaper.

One Nucleus facilitates the global competitiveness of its members by undertaking a number of activities that support their externalisation

EBD Group, organisers of the sector’s major bio-partnering conferences such as BioEurope, Biotech Showcase, BioPharm America and ChinaBio, are one of the latest One Nucleus Partners, and the support we have arranged with Flight Centre Business Travel allows members to maximise savings on trips to establish their external relationships.

Assay Depot: A key success factor in the externalised world is to have an optimised procurement strategy. One Nucleus’ collaboration with Assay Depot, based on the ‘Accessing Innovation Marketplace’ strategy deployed by AstraZeneca, affords its members a number of benefits in sourcing innovative solutions, reliable R&D services and cost savings through the online platform. Joining the One Nucleus Marketplace provides our members with benefits that include: • Waiving of the US $10,000 set up fee for buyers of R&D services.

• Ability to search for the latest

• A star-rating system of vendors by other buyers to provide comfort and build reputation for buyers and sellers, respectively.

Source R&D: The collaboration between One Nucleus and Bionow.

We successfully launched the inaugural edition of Source R&D at Genesis 2014 and was such a success that the organisations plan to release the updated edition at Genesis 2015. The excellence, capacity and value of our members in this field will be showcased through basic directory listings for R&D service providers, with enhanced profile options for advertisers and scene-setting editorial from industry experts.

Previewing at Genesis 2015 will be Source Clinical, a sister publication that showcases providers and expertise in clinical development.

Tony Jones, Director of Business Development

One Nucleus News

Autumn 2015

27

The Life Science Leadership Series The Life Science Leadership Series of events are themed by technology focus, therapeutic area or industry challenge. Current approaches, challenges and potential solutions are presented to and debated with a peer group of up to 100 attendees active in the area. Collective sharing and discussion of the major issues ensure the participants leave better informed and better equipped to develop strategies to enhance their own business’ global competitiveness.

On 20 May, attendees gathered at Chesterford Research Park to discuss the challenges of Antimicrobial Resistance and how to tackle them. Anti-microbial resistance is of growing global concern, with England’s Chief Medical Officer, Dame Sally Davies, recently describing it as a ‘ticking time bomb’. The speakers at this

event set out their perspectives of the challenges, and outlined how emerging technologies are leading the way to create innovative intervention strategies.

Presentations can be seen here http://onenucleus.com/onenucleusevents?id=859

of designing clinical trials including early data packaging, licensing, selecting a development partner, patient-group engagement and, more broadly, how to make a business case for investment in a drug development programme.

Presentations can be seen http:// www.onenucleus.com/onenucleusOn 24 September the last leadership events?id=866 event of 2015 which focused on Strategies and Funding One Nucleus is always keen to hear of Clinical Trials. The event from sector specialists, so if you combined keynote presentations would like to be involved in one of and panel discussions on the the Life Science Leadership Series drivers that lead to questioning or have views on future events or clinical trial strategies, and practical topics for discussion, do please presentations on how to design contact Aline, aline@onenucleus. clinical trials. Speakers discussed com the rise of regulatory hurdles, population demographics, precision The next event is 11 February, medicines and patient stratification Respiratory and Inflammation, that are challenging the systems Chesterford Research Park. of all healthcare providers and payers. The afternoon session then Aline Charpentier, Business Development Manager addressed the actual practicalities

Working with Our Patron, Corporate Sponsors and Partners: an update Those organisations seeking to engage across the One Nucleus membership and play a central role in the sector have continued to leverage the range of platforms One Nucleus provides.

The past six months have seen Johnson & Johnson Innovation become one of our Corporate Sponsors. The company’s bespoke activities included hosting the highly successful One Nucleus BIO Executive Dinner in Philadelphia in June, and it will be presenting one of the plenary talks at the forthcoming Genesis Conference.

Amgen, a recent addition to the Partner Programme, worked with One Nucleus to deliver an Amgen Partnering Day to a capacity audience at the British Library in July. Our Corporate Patron MedImmune’s Bahija Jallal opened the ON Helix Conference, setting the scene for a great day of debate

around factors influencing the success of collaborations.

seminar on ‘Genomics in R&D and partnering’. Our commercial intelligence partners, SCRIP Penningtons Manches has enabled Intelligence and PharmaVentures One Nucleus members to update continue to provide insight and their business knowledge by hosting content for our events and offer breakfast sessions on ‘Immigration’ One Nucleus members significant and ‘Termination clauses of R&D discounts. The latest partners to agreements’, whilst we have seen join the One Nucleus Partner family Charles Russell Speechlys hosted include Lilly, Covance, Assay Depot, events on ‘Working with London’s United Airlines, EBD Group and the technology transfer offices’ and, Sanger Institute as we expand the in June, hosted our ‘Healthcare depth and breadth of strong support investment trends’ seminar with brought to our members. the London Stock Exchange, BIA, MedCity and Hume Brophy.

For information on how to become a sponsor or partner please download Our partners providing R&D the brochure www.onenucleus.com/ facilities, such as Stevenage download.aspx?id=1554 and review Bioscience Catalyst, London our website www.onenucleus.com/ Bioscience Innovation Centre, sponsorship Queen Mary BioEnterprises, Chesterford Research Park and Babraham BioScience Technologies have all hosted One Nucleus events. Tony Jones, Director of Business LabCorp/Covance led our leadership Development

28

One Nucleus News

Autumn 2015

Facilities Management Don’t forget that One Nucleus offers purchasing and budgeting.

Facilities Management consultancy Currently consulting at Cantab to members at a discounted rate.

Biopharmaceuticals, Fahy Richard Dickinson (richard@ Gurteen Laboratories, Abzena , onenucleus.com or 01223 896453), Aqdot and Agenus, Richard has One Nucleus’ Director of Specialist previously consulted for a number Services, has over 15 years’ of One Nucleus members on experience as a Facilities Manager various projects including Astex and worked for more than 20 years Therapeutics, Babraham Bioscience in the life science sector.

Technologies, Pathology Diagnostics, Zoragen, Origin Sciences, Iontas Richard provides project and Spirogen. management for office and laboratory fit-outs and can advise Richard can provide help by phone on equipment service contracts, or email as well as providing full maintenance contracts, cleaning onsite consultancy. contracts, utility bills, insurance,

Director of Specialist Services

Consultancy Day Rate

Gold Members

Silver Members

Non Members

£535

£650

£800

Purchasing In August, Sigma Aldrich uploaded a list of new discounts on GE products ranging from 17.5% 23% discount, please contact Jon Rock at jon.rock@sial.com for more information.

The current Laboratory Products and Associated Services Preferred Supplier Agreement (PSA) with Fisher Scientific comes to an end on 31 December 2015. Covering

laboratory consumables, chemicals and low value apparatus, the new tender process will start in September with a new contract commencing on the 2 January 2016.

Support Suppliers Company

SSA

Gilson UK Ltd

Strem Chemicals UK Ltd

Email

Phone

Liquid Chromatography, Solid Phase Susanna Lovell Extraction, Liquid Handling and Gel Permeation Chromatography Equipment

Slovell@gilsonuk.com

07771 580815

High Purity Chemicals and Speciality Materials

enquiries@strem.co.uk

08456 437263

Our Support Suppliers list continues to grow and offer discounts to ALL our members. For the full list please see the Purchasing pages on the One Nucleus website.

Contact

Debra or Nigel

We can perform a cost-benefit analysis for Silver members thinking of upgrading to Gold or new companies wishing to join as Gold members. Please contact Richard

Dickinson on 01223 896453 or richard@onenucleus.com

One Nucleus News

Dates for your Diary 2015/2016 APR 20

NOV 11

BioWednesday Queen Mary BioEnterprises, London

NOV 18

Network Meeting Stevenage Bioscience Catalyst

DEC 10

Genesis QEII, London

2016

Autumn 2015

Network Meeting Taylor Vinters, Cambridge

MAY 04

BioWednesday EIP, London

JUN 28

ON Helix Wellcome Genome Campus, Conference Centre, Cambridge

JUL 06

BioWednesday LBIC, London

JUL 13

Network Meeting Summer Social Granta Park, Cambridge

SEP 07

BioWednesday Wragg Lawrence & Co, London

OCT 05

BioWednesday Queen Mary BioEnterprises, London

OCT 12

Network Meeting Deloitte, Cambridge

JAN 06

BioWednesday Social London

JAN 26

Network Meeting Social Cambridge

FEB 03

BioWednesday Olswang, London

FEB 11

Life Science Leadership Series Respiratory and Inflammation Chesterford Research Park, Cambridge

NOV 02

Network Meeting Cambridge

BioWednesday Queen Mary BioEnterprises, London

DEC 01

Genesis QE II Centre, London

Network Meeting Cambridge City Hotel, Cambridge

DEC 14

Network Meeting Cambridge Airport, Cambridge

MAR 02

MAR 23

29

One Nucleus News

New Members 14M Genomics Accelovance Europe Ltd Agility Health Tech APCure Auspherix Ltd Autolus Ltd Avacta Life Sciences Ltd Avocado Research Chemicals T/A Alfa Aesar Axonal BioNJ Inc BioPlus Tech Ltd Bio-Rad Laboratories Ltd (package deal) BioVentures Consulting Ltd Century Genomics Ltd Clinuvel (UK) Ltd Consultant - Carrie Adelman Consultant - Tamara Pedgrift Cypralis Ltd Elsevier B.V. eras Euromedica Executive Search Ltd

Autumn 2015

Oxford Biotrans Limited

Eventum Partners

Paul Hastings (Europe) LLP

Evonetix

Pharmanswers Ltd

Fairjourney Biologics

Plasticell

GeneAdvisor Gilson UK Hayward Medical Communications HUREKA Resources Ltd

Remtec Search and Selection Ltd Reneuron Group plc

IDACO Consulting Ltd

Reviresco Solutions

Infoset Europe Ltd

Sahlgrenska Science Park

Inngenii Ltd

Selvita Ltd

Innovate UK

Simon Bennett Associates Ltd

LabXero Ltd Life Sciences Sharing Ideas (LSSI) Ltd LIFT BioSciences Ltd London School of Clinical Research LucyJRobertshaw Miramar Executive Search Ltd Mitch Rogers Associates

QED Life Sciences Limited Redx Pharma Plc

SmithsonHill Ltd Susan R. Windham-Bannister Synergy Health Pharmaceutical Laboratories Synexus Ltd Takara Clontech The Assay Depot Inc

Moore Stephens LLP

Trilogy Writing & Consulting Ltd

Novozymes Biopharma UK Ltd Opticore Medical Ltd

TTS Ltd United Airlines

Ossianix

WuXi AppTec UK Ltd

One Nucleus Sponsors Corporate Patron

Corporate Sponsors

Partners

Media Partners

The One Nucleus ON Highlights is written by individuals and is not necessarily a reflection of the views held by One Nucleus.

28 June 2016 Cambridge,UK

Translating UK scientific excellence into global therapeutic strategies

onhelix.com

Our translational research conference

London’s premier Life Science & Healthcare networking conference

genesis 2016 Taking Bio-Innovation to a Global Market 1 December 2016 QEII Centre, Westminster, London, UK

genesisconference.com